A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG).
about
123I-MIBG scintigraphy and 18F-FDG-PET imaging for diagnosing neuroblastomaA clinical role for [(123)I]MIBG myocardial scintigraphy in the distinction between dementia of the Alzheimer's-type and dementia with Lewy bodiesClinical Implications of Cardiac-MIBG SPECT in the Differentiation of Parkinsonian Syndromes.New imaging approaches to phaeochromocytomas and paragangliomas.Diagnostic accuracy of apparent diffusion coefficient and 123I-metaiodobenzylguanidine for differentiation of multiple system atrophy and Parkinson's disease.123I-MIBG cardiac uptake and smell identification in parkinsonian patients with LRRK2 mutationsEffects of cardiac sympathetic innervation on regional wall motion abnormality in patients with long QT syndromeRepeated Radionuclide therapy in metastatic paraganglioma leading to the highest reported cumulative activity of 131I-MIBG.Pheochromocytoma and paraganglioma: current functional and future molecular imaging.Cardiac 123I-MIBG scintigraphy in patients with drug induced parkinsonism.False-negative ¹²³I-MIBG SPECT is most commonly found in SDHB-related pheochromocytoma or paraganglioma with high frequency to develop metastatic disease.Diagnostic value of MIBG cardiac scintigraphy for differential dementia diagnosis.Utility of the combination of DAT SPECT and MIBG myocardial scintigraphy in differentiating dementia with Lewy bodies from Alzheimer's diseasePheochromocytoma and paraganglioma.EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma.Counseling patients with succinate dehydrogenase subunit defects: genetics, preventive guidelines, and dealing with uncertainty.Pitfalls in paediatric oncology imaging.Current perioperative management of pheochromocytomas.Nuclear medicine imaging in the evaluation of endocrine hypertension.Diagnostic and Pathophysiological Impact of Myocardial MIBG Scintigraphy in Parkinson's Disease.A Case of a "Voiding" Hypertension.Role of Neuroimaging as a Biomarker for Neurodegenerative Diseases.
P2860
Q24186888-9B93F754-6887-4CB8-A7FE-A329D003C570Q28362147-C65A49E0-B033-49FE-8C65-6ACC2329EC80Q33790729-33AB8884-EB23-485A-BBED-845146D2FE4CQ34255457-4E502139-17C7-40DD-A0CF-C5957A4C3778Q34683979-55E8B471-8E6A-48DD-8A11-4863C2D40A59Q35004642-8F210F79-34F0-486E-AB02-73D484524782Q35375182-6EDE6C83-3C6C-4B85-A6A3-516FAB7126D3Q35750737-D8333B8E-7ABB-457F-87B5-E5DF5852906BQ35972320-2CCB1E37-8680-4CE8-B965-53D5CF5CBFFCQ36143071-327B709E-A022-4301-A301-3EF962E0BEC9Q36167038-DC33A674-6C9C-4D8A-A637-6A7D9CE7E177Q36311270-47ECB65B-128C-4BE4-A9E3-4F4D93CBE49AQ36373719-A61ACC72-3274-474B-90CB-14AB7C25D290Q36467162-BFC64EC7-3ACC-4BBF-AA3F-F9C9BB316031Q36467722-9BF0699D-974B-46D2-B470-DD81D1949E76Q36477785-7CA01D40-1228-4219-8C56-F7EE44BEE3DAQ37946579-026163D3-F9CA-4B92-B3A7-FB8C650C4100Q39135536-D4F943D3-A820-436A-A881-F786E31A7128Q41839681-94B29345-522A-49DA-9201-FABB659A2034Q42408447-1BFBCC45-9A71-4343-92B2-C2E78454C2DBQ47134854-7F32F6B7-6184-4A6B-B214-7A59C1603D30Q55344088-C8639860-5BE6-482B-84E8-24DC3BF8A9F2
P2860
A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG).
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
1992年论文
@zh
1992年论文
@zh-cn
name
A pharmacological guide to med ...... ta-iodobenzylguanidine (MIBG).
@ast
A pharmacological guide to med ...... ta-iodobenzylguanidine (MIBG).
@en
type
label
A pharmacological guide to med ...... ta-iodobenzylguanidine (MIBG).
@ast
A pharmacological guide to med ...... ta-iodobenzylguanidine (MIBG).
@en
prefLabel
A pharmacological guide to med ...... ta-iodobenzylguanidine (MIBG).
@ast
A pharmacological guide to med ...... ta-iodobenzylguanidine (MIBG).
@en
P2093
P1476
A pharmacological guide to med ...... ta-iodobenzylguanidine (MIBG).
@en
P2093
P304
P577
1992-07-01T00:00:00Z